- Home
- MRCC vs OTLK Comparison
MRCC vs OTLK Comparison
Compare MRCC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- OTLK
- Stock Information
- Founded
- MRCC 2011
- OTLK 2010
- Country
- MRCC United States
- OTLK United States
- Employees
- MRCC N/A
- OTLK N/A
- Industry
- MRCC Investment Managers
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRCC Finance
- OTLK Health Care
- Exchange
- MRCC Nasdaq
- OTLK Nasdaq
- Market Cap
- MRCC 171.4M
- OTLK 178.6M
- IPO Year
- MRCC 2012
- OTLK 2016
- Fundamental
- Price
- MRCC $7.91
- OTLK $7.95
- Analyst Decision
- MRCC Strong Buy
- OTLK Strong Buy
- Analyst Count
- MRCC 1
- OTLK 7
- Target Price
- MRCC $9.00
- OTLK $48.20
- AVG Volume (30 Days)
- MRCC 41.3K
- OTLK 153.1K
- Earning Date
- MRCC 08-07-2024
- OTLK 08-14-2024
- Dividend Yield
- MRCC 12.64%
- OTLK N/A
- EPS Growth
- MRCC 194.63
- OTLK N/A
- EPS
- MRCC 0.36
- OTLK N/A
- Revenue
- MRCC $61,955,000.00
- OTLK N/A
- Revenue This Year
- MRCC N/A
- OTLK N/A
- Revenue Next Year
- MRCC N/A
- OTLK N/A
- P/E Ratio
- MRCC $21.97
- OTLK N/A
- Revenue Growth
- MRCC N/A
- OTLK N/A
- 52 Week Low
- MRCC $6.69
- OTLK $4.00
- 52 Week High
- MRCC $8.04
- OTLK $18.00
- Technical
- Relative Strength Index (RSI)
- MRCC 59.86
- OTLK 56.05
- Support Level
- MRCC $7.73
- OTLK $6.61
- Resistance Level
- MRCC $7.89
- OTLK $7.89
- Average True Range (ATR)
- MRCC 0.15
- OTLK 0.45
- MACD
- MRCC 0.02
- OTLK 0.06
- Stochastic Oscillator
- MRCC 74.51
- OTLK 94.36
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.